Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Michael  Varney - Executive Vice President, Genentech Research and Early Development

Michael Varney

Executive Vice President, Genentech Research and Early Development

"I like building teams to solve hard problems."
Years at Genentech

I joined Genentech in June of 2005 as Vice President, Small Molecule Drug Discovery. In 2010 I was named Senior Vice President, Research and Small Molecules, and I am currently Executive Vice President, Genentech Research and Early Development. In this role, I am responsible for the management of all aspects of our drug discovery and drug development activities. In addition, I am a member of the Genentech Executive Committee and a member of the expanded Corporate Executive Committee for Roche.

I was attracted to Genentech because of my long-standing interest in translating excellent science into therapies to treat unmet medical needs. I continue to be excited by the prospect of utilizing Genentech's deep expertise in biology to discover and develop novel and innovative drug molecules of all types to contribute to the health and well being of our community. I like the idea of building large diverse teams of highly skilled scientists who work together to solve very difficult problems.

Featured Publication

Biological properties of AG2037: a new inhibitor of glycinamide ribonucleotide formyltransferase with low affinity for the folate receptor

Proc Am Assoc Cancer Res 40(90); 291-92

Bartlett, C. A., Boritzki, T. J., Dagostino, E. F., Margosiak, S. A., Palmer, C. L., Romines, W. H., Varney, M. D